Parkinson's Disease clinical trials at UC Irvine

• A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

  open to eligible people ages 30-80

  This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders. For more information, please visit: www.PrismPDstudy.com

  Irvine, California and other locations

• GDNF Gene Therapy for Parkinson's Disease

  open to eligible people ages 35-75

  The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.

  Irvine, California and other locations

• Light Therapy for PD - Dose Selection

  open to eligible people ages 45 years and up

  This study aims to determine the most effective dose of light therapy to improve sleep in people with Parkinson's Disease. Four groups of participants will receive bright-white or dim-red light therapy at different times throughout the day.

  Irvine, California and other locations

• Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

  open to eligible people ages 50-76

  This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.

  Orange, California and other locations

• VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

  Sorry, in progress, not accepting new patients

  The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.

  Irvine, California and other locations

Last updated: June 21, 2021